Supplementary Material for: Cell-Derived Microparticles in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-Analysis

<i>Background/Aims: </i>The aim of this study was to assess the association between circulating cell-derived microparticles (MPs) and type 2 diabetes mellitus (T2DM). <i>Methods: </i>A literature search was performed systematically in PubMed and Embase to identify available case-control or cross-sectional studies that compared different types of cell-derived MPs in patients with T2DM and non-diabetic controls. Pooled standardized mean differences (SMDs) of each MP type were pooled using meta-analysis. <i>Results: </i>Forty-eight studies involving 2,460 patients with T2DM and 1,880 non-diabetic controls were included for systematic review and 34 of which were included for quantitative study by meta-analysis. In the overall analysis, the levels of circulating total MPs (TMPs), platelet-derived MPs (PMPs), monocyte-derived MPs (MMPs) and endothelium-derived MPs (EMPs) were significantly higher in T2DM patients than those in controls (TMPs: SMD, 0.64; 95%CI, 0.12∼1.15; P=0.02; PMPs: SMD, 1.19; 95%CI, 0.88∼1.50; P &lt;0.00001; MMPs: SMD, 0.92; 95%CI, 0.66∼1.17; P &lt;0.00001; EMPs: SMD, 0.73; 95%CI, 0.50∼0.96; P &lt;0.00001). Meanwhile, no significant difference was shown in leukocyte-derived MPs (LMPs) level between diabetic and non-diabetic groups (SMD, 0.37; 95%CI, -0.15∼0.89; P=0.17). <i>Conclusions: </i>The counts of TMPs, PMPs, MMPs and EMPs elevated in patients with T2DM. And cell-derived MPs may play a role in the pathogenesis of T2DM.**背景与目的**：本研究旨在探讨循环细胞来源微粒（cell-derived microparticles, MPs）与2型糖尿病（type 2 diabetes mellitus, T2DM）之间的关联。**方法**：系统检索PubMed及Embase数据库，筛选对比2型糖尿病患者与非糖尿病对照人群各类细胞来源微粒水平的病例对照或横断面研究，采用荟萃分析合并各类微粒的标准化均数差（standardized mean differences, SMDs）。**结果**：本系统评价共纳入48项研究，涉及2460例2型糖尿病患者与1880例非糖尿病对照人群，其中34项研究被纳入定量荟萃分析。整体分析显示，2型糖尿病患者的循环总微粒（total MPs, TMPs）、血小板来源微粒（platelet-derived MPs, PMPs）、单核细胞来源微粒（monocyte-derived MPs, MMPs）及内皮细胞来源微粒（endothelium-derived MPs, EMPs）水平均显著高于对照组（TMPs：标准化均数差SMD=0.64，95%置信区间CI：0.12~1.15，P=0.02；PMPs：SMD=1.19，95%CI：0.88~1.50，P<0.00001；MMPs：SMD=0.92，95%CI：0.66~1.17，P<0.00001；EMPs：SMD=0.73，95%CI：0.50~0.96，P<0.00001）。同时，白细胞来源微粒（leukocyte-derived MPs, LMPs）水平在糖尿病组与非糖尿病组间无显著差异（SMD=0.37，95%CI：-0.15~0.89，P=0.17）。**结论**：2型糖尿病患者的循环总微粒、血小板来源微粒、单核细胞来源微粒及内皮细胞来源微粒计数均升高，细胞来源微粒可能在2型糖尿病的发病机制中发挥作用。